Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Following these transactions, the reporting entities hold a significant stake in New Amsterdam Pharmacy, totaling 10,686,018 shares. Despite the sale, Forbion’s constituents remain major shareholders in the company, the shares were part of a structured scheme through the indirect collective investment vehicle, ForGrowth NAP BV Transactions, and the shares were sold in multiple transactions at stated prices. . The reporting entities are committed to providing full details of the transaction upon request. Investors can access the full Pro Research report available to get an in-depth understanding of NAMS’s assessment and overall analysis. Invest ProIt covers over 1,400 US stocks with expert analysis and actionable information. Investors can access the full Pro Research report available to get an in-depth understanding of NAMS’s assessment and overall analysis. Invest ProIt covers over 1,400 US stocks with expert analysis and actionable information.
Following these transactions, the reporting entities hold a significant stake in New Amsterdam Pharmacy, totaling 10,686,018 shares. Despite the sale, Forbion’s constituents remain major shareholders in the company, the shares were part of a structured scheme through the indirect collective investment vehicle, ForGrowth NAP BV Transactions, and the shares were sold in multiple transactions at stated prices. . The reporting entities are committed to providing full details of the transaction upon request. Investors can access the full Pro Research report available to get an in-depth understanding of NAMS’s assessment and overall analysis. Invest ProIt covers over 1,400 US stocks with expert analysis and actionable information.
Following these transactions, the reporting entities hold a significant stake in New Amsterdam Pharmacy, totaling 10,686,018 shares. Despite the sale, Forbion’s constituents will remain major shareholders in the company, with the shares held indirectly through their joint investment vehicle, ForGrowth NAP BV.
The transactions were part of a structured plan, and the shares were traded in multiple transactions at prices within specified ranges. The reporting entities are committed to providing full details of the transaction upon request.
In other recent news, NewAmsterdam Pharma Co NV has seen several major developments. The company’s lead drug candidate obisetrapib showed promising results in phase 3 trials, which HC Wainwright Bank of Scotland (TSX: ), and Leerink Partners to give positive ratings and price targets. The drug showed significant reductions in LDL-C cholesterol levels and major adverse cardiovascular events.
In addition, New Amsterdam Pharma has suspended and withdrawn an automated teller machine (ATM) prospectus previously filed in connection with a $150 million share sale plan. The company restated its financial statements for the years 2022 and 2021 due to errors in the calculation of gross net loss and welcomed new board members Mark C. McKenna and Wouter Jostra.
Looking forward, NewAmsterdam is gearing up for the Pelacarson Phase 3 HORIZON trial in 2025 and the Phase 3 BROADWAY trial expected in the fourth quarter of 2024. These are the latest developments for NewAmsterdam Pharma.
This article was created by AI Support and reviewed by an editor. See our T&C for more information.
